专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08716527B2 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases 有权
标题翻译：用于治疗氧化应激疾病的2-取代的对醌衍生物
公开(公告)号：US08716527B2
公开(公告)日：2014-05-06
申请号：US12919007
申请日：2009-03-04
申请人： Andrew W. Hinman , Kieron E. Wesson , Orion D. Jankowski , Paul Mollard , William D. Shrader , Christopher R. Cornell
发明人： Andrew W. Hinman , Kieron E. Wesson , Orion D. Jankowski , Paul Mollard , William D. Shrader , Christopher R. Cornell
IPC分类号： C07C233/05 , A61K31/65 , C07D209/04 , C07D211/00 , A61K31/445 , A61K31/40
CPC分类号： C07D295/195 , A61P21/00 , A61P25/00 , C07C45/00 , C07C45/30 , C07C205/34 , C07C233/31 , C07C233/61 , C07C233/76 , C07C235/34 , C07C235/40 , C07C235/78 , C07C255/57 , C07C255/60 , C07C275/22 , C07C275/30 , C07C311/03 , C07C311/16 , C07C311/17 , C07C311/29 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07D209/08 , C07D211/46 , C07D213/56 , C07D213/75 , C07D213/82 , C07D215/08 , C07D217/06 , C07D295/215 , C07D311/74 , C07D317/66 , C07D319/18 , C07D339/04 , C07C47/575 , C07C47/277
摘要： Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2- substituted-p-quinone derivatives as disclosed herein.
摘要翻译：公开了治疗或抑制包括线粒体疾病，受损能量加工障碍，神经变性疾病和衰老疾病的氧化应激疾病的方法，以及可用于本发明方法的化合物，例如所公开的2-取代对醌衍生物这里。

2. 发明申请

US20110124679A1 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES 有权
标题翻译：用于治疗氧化应激疾病的2-取代对 - 对 - 喹奴酮衍生物
公开(公告)号：US20110124679A1
公开(公告)日：2011-05-26
申请号：US12919007
申请日：2009-03-04
申请人： Andrew W. Hinman , Kieron E. Wesson , Orion D. Jankowski , Paul Mollard , William D. Shrader , Christpher R. Cornell
发明人： Andrew W. Hinman , Kieron E. Wesson , Orion D. Jankowski , Paul Mollard , William D. Shrader , Christpher R. Cornell
IPC分类号： A61K31/47 , A61K31/445 , A61K31/44 , A61K31/405 , A61K31/40 , A61K31/335 , A61K31/165 , C07D217/00 , C07D211/00 , C07D213/73 , C07D209/04 , C07D209/44 , C07D319/14 , C07C233/00
CPC分类号： C07D295/195 , A61P21/00 , A61P25/00 , C07C45/00 , C07C45/30 , C07C205/34 , C07C233/31 , C07C233/61 , C07C233/76 , C07C235/34 , C07C235/40 , C07C235/78 , C07C255/57 , C07C255/60 , C07C275/22 , C07C275/30 , C07C311/03 , C07C311/16 , C07C311/17 , C07C311/29 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07D209/08 , C07D211/46 , C07D213/56 , C07D213/75 , C07D213/82 , C07D215/08 , C07D217/06 , C07D295/215 , C07D311/74 , C07D317/66 , C07D319/18 , C07D339/04 , C07C47/575 , C07C47/277
摘要： Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.
摘要翻译：公开了治疗或抑制包括线粒体疾病，受损能量加工障碍，神经变性疾病和衰老疾病的氧化应激疾病的方法，以及可用于本发明方法的化合物，例如所公开的2-取代对醌衍生物这里。

3. 发明授权

US07968746B2 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases 有权
标题翻译： 4-（对醌基）-2-羟基丁酰胺衍生物用于治疗线粒体疾病
公开(公告)号：US07968746B2
公开(公告)日：2011-06-28
申请号：US12264838
申请日：2008-11-04
申请人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
发明人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
IPC分类号： C07C233/00
CPC分类号： C07C235/80 , C07C235/78 , C07C317/28 , C07C2601/02 , C07C2601/16 , C07D207/26 , C07D207/27 , C07D211/46 , C07D213/40 , C07D213/50 , C07D233/61 , C07D265/30 , C07D295/116 , C07D295/13 , C07D295/185 , C07D295/192 , C07D311/66
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译：还公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），Leber氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落和中风（MELAS），Kearns-Sayre综合征（KSS）的方法作为可用于本发明方法的化合物，例如4-（对 - 喹啉基）-2-羟基丁酰胺衍生物。还公开了可用于治疗其他疾病如肌萎缩性侧索硬化（ALS），亨廷顿氏病，帕金森病和普遍发育障碍如自闭症的方法和化合物。还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。

4. 发明申请

US20090118257A1 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES 有权
标题翻译： 4-（对 - 喹啉）-2-羟基丁酰胺衍生物用于治疗麻醉性疾病
公开(公告)号：US20090118257A1
公开(公告)日：2009-05-07
申请号：US12264838
申请日：2008-11-04
申请人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
发明人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
IPC分类号： A61K31/16 , C07C235/72 , C07D211/06 , C07D223/02 , A61K31/55 , A61K31/445 , A61K31/4164 , A61K31/495 , C07D233/54 , C07D241/04 , A61P25/00
CPC分类号： C07C235/80 , C07C235/78 , C07C317/28 , C07C2601/02 , C07C2601/16 , C07D207/26 , C07D207/27 , C07D211/46 , C07D213/40 , C07D213/50 , C07D233/61 , C07D265/30 , C07D295/116 , C07D295/13 , C07D295/185 , C07D295/192 , C07D311/66
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译：还公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），Leber氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落和中风（MELAS），Kearns-Sayre综合征（KSS）的方法作为可用于本发明方法的化合物，例如4-（对 - 喹啉基）-2-羟基丁酰胺衍生物。还公开了可用于治疗其他疾病如肌萎缩性侧索硬化（ALS），亨廷顿氏病，帕金森病和普遍发育障碍如自闭症的方法和化合物。还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。

5. 发明授权

US08519001B2 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases 有权
公开(公告)号：US08519001B2
公开(公告)日：2013-08-27
申请号：US13110830
申请日：2011-05-18
申请人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
发明人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
IPC分类号： A01N37/18 , A61K31/165
CPC分类号： C07C235/80 , C07C235/78 , C07C317/28 , C07C2601/02 , C07C2601/16 , C07D207/26 , C07D207/27 , C07D211/46 , C07D213/40 , C07D213/50 , C07D233/61 , C07D265/30 , C07D295/116 , C07D295/13 , C07D295/185 , C07D295/192 , C07D311/66
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

6. 发明申请

US20120122934A1 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES 有权
标题翻译： 4-（对 - 喹啉）-2-羟基丁酰胺衍生物用于治疗麻醉性疾病
公开(公告)号：US20120122934A1
公开(公告)日：2012-05-17
申请号：US13110830
申请日：2011-05-18
申请人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
发明人： Orion D. Jankowski , Kieron E. Wesson , Paul Mollard , William D. Shrader
IPC分类号： A61K31/44 , A61K31/4015 , A61K31/165 , A61P3/10 , A61P27/02 , A61P25/16 , A61P25/28 , A61P25/08 , A61P25/18 , A61P35/00 , A61K31/4164 , A61P25/00
CPC分类号： C07C235/80 , C07C235/78 , C07C317/28 , C07C2601/02 , C07C2601/16 , C07D207/26 , C07D207/27 , C07D211/46 , C07D213/40 , C07D213/50 , C07D233/61 , C07D265/30 , C07D295/116 , C07D295/13 , C07D295/185 , C07D295/192 , C07D311/66
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译：还公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），Leber氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落和中风（MELAS），Kearns-Sayre综合征（KSS）的方法作为可用于本发明方法的化合物，例如4-（对 - 喹啉基）-2-羟基丁酰胺衍生物。还公开了可用于治疗其他疾病如肌萎缩性侧索硬化（ALS），亨廷顿氏病，帕金森病和普遍发育障碍如自闭症的方法和化合物。还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。

7. 发明授权

US09278085B2 Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers 有权
标题翻译：用于治疗线粒体疾病和其他条件的氧化还原活性治疗剂的侧链变体和能量生物标志物的调节
公开(公告)号：US09278085B2
公开(公告)日：2016-03-08
申请号：US11710042
申请日：2007-02-22
申请人： Guy M. Miller , Sidney M. Hecht , Orion D. Jankowski , Kieron E. Wesson , Paul Mollard
发明人： Guy M. Miller , Sidney M. Hecht , Orion D. Jankowski , Kieron E. Wesson , Paul Mollard
IPC分类号： A61K31/355 , A61K31/05 , C07C39/08 , C07C39/11 , C07C39/19 , C07C39/24 , C07C50/02 , C07C50/06 , C07C50/24 , C07C50/28 , C07C215/56 , C07C403/04 , C07C403/08 , C07C403/18
CPC分类号： C07C50/04 , A61K31/05 , A61K31/355 , C07C39/08 , C07C39/11 , C07C39/19 , C07C39/245 , C07C43/225 , C07C43/23 , C07C47/277 , C07C50/02 , C07C50/06 , C07C50/24 , C07C50/28 , C07C69/608 , C07C69/618 , C07C215/56 , C07C233/27 , C07C233/32 , C07C255/37 , C07C403/04 , C07C403/08 , C07C403/18 , C07C2601/16
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译：公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），莱伯氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落症，中风（MELAS）或Kearns-Sayre综合征（KSS）的方法，以及可用于本发明方法的化合物。还公开了可用于治疗其它疾病的方法和化合物。还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。

8. 发明申请

US20140249332A1 METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS 有权
标题翻译：在非ALPHA TOCOTRIENOLS存在下选择性氧化阿托伐他汀的方法
公开(公告)号：US20140249332A1
公开(公告)日：2014-09-04
申请号：US14233734
申请日：2012-07-19
申请人： Paul Mollard
发明人： Paul Mollard
IPC分类号： C07C46/06
CPC分类号： C07C46/06 , C07C403/08 , C07C2601/16 , C07D311/72 , C07C50/28
摘要： A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-tocotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs the non-alpha tocotrienol chromans.
摘要翻译：一种生产α-生育三烯酚醌或其立体异构体的方法，所述方法包括通过用金属盐氧化剂氧化α-生育三烯酚，在非α-生育三烯酚染料色素存在下选择性地将α-生育三烯酚苯并二氢吡喃酮打开至α-生育三烯酚醌金属盐氧化剂/α-生育三烯酚的化学计量比为至少4:1，并且其中所述金属氧化剂按顺序加入添加，以减少可能存在于任何量的非α-生育三烯酚黑色素的氧化起始的α-生育三烯酚色满物质。该方法使用有利于α-生育三烯酚苯并二氢吡喃酮与非α-生育三烯酚染料色素的氧化速率的条件。

9. 发明授权

US4808327A Compositions of particulate magnetic oxides with a defect spinel structure, preparation thereof and application thereof 失效
标题翻译：具有缺陷尖晶石结构的颗粒状磁性氧化物的组合物，其制备方法及其应用
公开(公告)号：US4808327A
公开(公告)日：1989-02-28
申请号：US62609
申请日：1987-06-01
申请人： Abel Rousset , Christiane B. Salvaing , Paul Mollard , Michel Gougeon , Philippe Tailhades
发明人： Abel Rousset , Christiane B. Salvaing , Paul Mollard , Michel Gougeon , Philippe Tailhades
IPC分类号： C01B13/18 , C01G49/00 , G11B5/706 , H01F1/11 , C04B35/26
CPC分类号： G11B5/70642 , C01B13/185 , C01G49/009 , C01P2002/32 , C01P2006/42
摘要： Particulate magnetic oxide compositions based on iron oxide (III) and oxide of at least one bivalent metal selected among cobalt, iron, copper, zinc, magnesium, nickel, manganese and cadmium, characterized in that said compositions contain additionally in the form of an oxide from 0.2 to 5% by weight calculated on the total weight at least one additive or substituent selected among alkali metals, alkaline-earth metals, boron, the elements of columns 3, 4 and 5 of the periodical classification of elements having a molecular mass higher than 26, the transition metals 3d and 4d other than those already mentioned, and the rare earths, with the proviso that when an alkali metal or tin is present, at least another additive or substituent is also present, and in that said compositions have a structure of the lanucar spinel type; the preparation and application thereof are also disclosed.
摘要翻译： PCT No.PCT / FR86 / 00337 Sec。 371日期：1987年6月1日 102（e）日期1987年6月1日PCT提交1986年9月30日PCT公布。公开号WO87 / 02173 日本1987年4月9日。基于氧化铁（III）和选自钴，铁，铜，锌，镁，镍，锰和镉中的至少一种二价金属的氧化物的颗粒状磁性氧化物组合物，其特征在于所述组合物含有另外以0.2至5重量％的氧化物的形式，其总重量计算为选自碱金属，碱土金属，硼中的至少一种添加剂或取代基，定期分类的第3,4和5列的元素的分子量高于26的元素，过渡金属3d和4d以外的已知的稀土元素和稀土元素，条件是当存在碱金属或锡时，还存在至少另一种添加剂或取代基，并且所述组合物具有兰卡尔尖晶石型结构; 还公开了其制备和应用。

10. 发明授权

US4004988A Method of preparing sodium chlorate by electrolysis 失效
标题翻译：电解法制备氯酸钠的方法
公开(公告)号：US4004988A
公开(公告)日：1977-01-25
申请号：US509057
申请日：1974-09-25
申请人： Paul Mollard , Pierre Lakodey
发明人： Paul Mollard , Pierre Lakodey
IPC分类号： C25B1/26
CPC分类号： C25B1/265
摘要： A method for preparing sodium chlorate comprises electrolyzing aqueous sodium chloride in the presence of at least one phosphorus-containing agent for complexing alkaline earth impurities, thereby advantageously extending the periods of uninterrupted satisfactory cell operation at substantially constant applied potential and facilitating the cleaning of electrodes between such periods.
摘要翻译：一种制备氯酸钠的方法包括在至少一种含磷试剂存在下电解氯化钠水溶液以络合碱土金属杂质，从而有利地将不间断的令人满意的电解池操作的时间延长到基本恒定的施加电位，并且有助于电极之间的清洁这样的时期。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式